**MINOCA presenting with STEMI – incidence, aetiology and outcome in a contemporaneous cohort**

Ying X. Gue MB BS, MRCP 1,2 \*, Natasha Corballis MB BS, MRCP 3\*, Alisdair Ryding MB BCh, MRCP, PhD 3,4, Juan Carlos Kaski DSc, MD, DM (Hons), FRCP 5†, Diana A. Gorog MB BS, MD, PhD 1,2,6†

1. University of Hertfordshire, Hertfordshire, United Kingdom

2. East and North Hertfordshire NHS Trust, Hertfordshire, United Kingdom

3. Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom

4. University of East Anglia, Norwich, United Kingdom

5. Molecular and Clinical Sciences Research Institute, St. George’s, University of London, United Kingdom

6. National Heart and Lung Institute, Imperial College, London, United Kingdom

\*these authors contributed equally to the manuscript (both residents/in early training)

† joint senior authors

Word count: 1514

Correspondence to:

Dr. Ying X Gue MB BS, MRCP

Cardiology Department

Lister Hospital

East and North Hertfordshire NHS Trust

Corey’s Mill Lane

Stevenage

Hertfordshire SG1 4AB

United Kingdom

Email: [y.gue@nhs.net](mailto:y.gue@nhs.net)

**ABSTRACT**

***Background***

Historical data indicate that approximately 10% of acute coronary syndrome patients have no obstructive coronary artery disease (CAD) but contemporary incidence of non-obstructed coronary arteries in ST-segment elevation myocardial infarction (STEMI) is not clear. We aimed both to identify the contemporary incidence of MI without obstructive CAD (MINOCA) -using the ESC definition- and assess clinical outcomes.

***Methods***

We assessed consecutive unselected STEMI patients presenting to the cardiac catheterisation laboratory with a view to undergoing primary percutaneous coronary intervention (PPCI). MINOCA was defined according to ESC criteria. Electronic patient records, blood results, angiographic and echocardiographic data were interrogated to determine final diagnosis, as well as 30-day and 1-year mortality rate.

***Results***

Of 2521 patients with full electronic dataset, 2158 (85.6%) underwent PPCI for obstructive CAD (angiographic stenosis >70%). A further 167 (6.6%) with obstructive CAD were treated medically or surgically. The remaining 196 (7.8%) patients had absence of obstructive CAD at angiography, of whom 167 had no stenosis (<30%) and 29 had mild coronary atheroma (stenosis >30% but <50%). A total of 110 (4.4%) patients met diagnostic criteria for MINOCA. All-cause mortality at 30-days and 1-year were 3.6% and 4.5%, respectively.

***Conclusion***

In our cohort, 1 in 20 patients presenting with STEMI had MINOCA. This is the first description of the relatively high incidence of MINOCA in a STEMI cohort using current ESC definition and diagnostic criteria and could help power future trials in this area. Mortality rate was relatively high in our study and similar to that in large meta-analyses.

Word count: 251

**Key words**

Myocardial infarction

MINOCA

STEMI

Mortality

# Introduction

# Approximately 90% of patients with myocardial infarction have angiographic evidence of obstructive coronary artery disease (CAD) based on registry studies published more than 30 years ago.1,2 The realisation that obstructive CAD was causative in the majority of patients with ST-segment elevation myocardial infarction (STEMI), led to the development of current management strategies including primary percutaneous coronary intervention (PPCI). In contrast to the clear aetiology and guidelines for the management of STEMI with CAD, in the 10% of patients who experience myocardial infarction in the absence of obstructive CAD, the aetiology is often obscure and optimal management unclear.3 Until recently, myocardial infarction with non-obstructive coronary arteries (MINOCA) was a “Cinderella” condition: little known, little understood and under-appreciated. In 2015, Pasupathy and co-workers published a comprehensive systematic review of patients with suspected myocardial infarction without obstructive CAD4 and in 2017, the European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacotherapy published a position paper which was, arguably, the first authoritative statement on definition, clinical features and recommended investigations in patients with MINOCA.5

Although a large registry of patients with non-ST-elevation myocardial infarction published 10 years ago showed the incidence of non-obstructive CAD to be 10%,6 another registry around the same time showed the incidence of angiographically normal coronaries in acute coronary syndrome to be only 2.8%.7 These studies did not define the incidence of MINOCA in STEMI, and MINOCA definition was not based on contemporary criteria.

MINOCA is not a benign condition; a meta-analysis indicated that 1-year all-cause mortality was 4.7%.4 More recently, data from the 2003-2013 SWEDEHEART registry revealed that over a 4-year follow-up, 23.9% patients with MINOCA experienced a major cardiac event.8

Establishing the true incidence of MINOCA among patients presenting with STEMI is important as these patients may require specific emergency investigation and *ad hoc* treatments that may differ from those currently recommended in conventional CAD STEMI. Future trials of new treatments for MINOCA STEMI patients will need to be adequately powered based on contemporary incidence, aetiology and outcomes.

It was our aim to identify the contemporary incidence of MINOCA amongst patients with ST-segment elevation, delineate the underlying diagnoses using the ESC definition5 and assess 1-year clinical outcomes.

# Methods

We assessed all consecutive patients with ST-elevation admitted with a view to PPCI, to East and North Hertfordshire NHS Trust and Norfolk and Norwich University Hospital, United Kingdom. These Heart Attack Centres (HAC) serve a population of 1.5 million, supported by East of England Ambulance Service NHS Trust. According to standard protocol, all patients who meet the criteria for STEMI are brought directly to the HAC for emergency PPCI. Criteria for PPCI protocol activation are symptoms compatible with an acute myocardial infarction within 12 hours with any of the following electrocardiographic (ECG) criteria: ST-segment elevation ≥1mm in contiguous limb leads, >2mm in contiguous chest leads, bundle branch block believed to be new in the context of acute cardiac-sounding chest pain, or patients resuscitated from cardiac arrest with ECG criteria as above. All patients who met these criteria were included.

Patients with MINOCA according to the ESC position paper and InterTAK Diagnostic Criteria5,9 were identified by review of all cases in the HAC activation database.

Initial MINOCA screening diagnosis required the presence of all of the following criteria:

(1) meet Universal Definition of Acute Myocardial Infarction criteria10

(2) no obstructive CAD at angiography, defined as no stenosis (diameter reduction) ≥50% in any potential infarct-related artery

(3) no other clinically-overt cause for the specific presentation.

Patients were identified using a predefined flowchart (Figure 1) to ensure a standardised approach. Electronic patient records, blood results, angiographic data and echocardiographic data were used to determine diagnosis, based on ESC recommendations for diagnostic work-up.11

# Results

We assessed 2521 consecutive unselected patients with ST-elevation fulfilling criteria for PPCI, with full electronic dataset (Figure 2). Of these, 85.6% underwent PPCI for obstructive CAD. A further 6.6% patients with obstructive CAD were treated medically or with surgical revascularisation. Angiographically-significant CAD was absent in 7.8% patients. A total of 110 patients (4.4% of all STEMIs) met diagnostic criteria for MINOCA, 54% were male, with mean age 63.5±13.9 years.

The aetiology of MINOCA was determined to be a coronary cause in 28%, non-coronary cardiac cause in 61% and non-coronary extra-cardiac cause in 11% of patients. Coronary causes included plaque disruption (39%), coronary spasm (10%), spontaneous coronary artery dissection (19%), coronary embolism (23%) and aortic dissection (10%).

Non-coronary cardiac causes included myocarditis (36%), Takotsubo syndrome (30%) and type 2 myocardial infarction (34%) – the latter comprising patients with cardiomyopathy, anaemia, valvular disease and arrhythmia.

Non-coronary (extra-cardiac) causes included pulmonary embolism (50%), cerebrovascular event (8%), and other causes included sepsis, gallstone pancreatitis and extracardiac tumour compressing the heart.

In the remaining 86 patients with absence of angiographically-significant CAD, the final diagnoses were predominantly pericarditis, myocarditis and normal-variant ECG.

In MINOCA patients, 30-day all-cause mortality was 3.6% and 1-year mortality was 4.5%.

# Discussion

The main findings of our study are that the incidence of MINOCA in a contemporary cohort of patients presenting with STEMI is 4.4%, and that 30-day and 1-year mortality rate are 3.6% and 4.5%, respectively.

The incidence of MINOCA -using the diagnostic criteria proposed by the Agewall position paper5 and specifically within the STEMI and PPCI setting- has not been reported previously. Knowing the incidence is important for planning future studies of treatment for this cohort, particularly in the acute phase, as treatments may differ markedly between STEMI patients with CAD and MINOCA patients. In the most recent publication on the incidence of this condition in STEMI, derived from the HORIZONS-AMI trial conducted >10 years ago, the reported incidence of “apical ballooning syndrome” based on the Mayo Clinic diagnostic criteria was 0.5% in 2648 STEMI patients.12 In the largest systematic review by Pasupathy and co-workers, the incidence of MINOCA was reported to be 6% amongst patients with acute coronary syndromes,4 but the incidence specifically in patients presenting with STEMI was not defined. This is very much lower than that reported in a retrospective analysis of the PRAGUE studies from pre-2002, in which the incidence of angiographically normal coronary arteries in 1004 emergency angiograms performed for STEMI, was reported as 26%.13 Although in the systematic review, some 30% of patients with MINOCA were reported to present with ST-segment elevation,4 in the SWEDEHEART registry of MINOCA patients from 2003-2013, only 17% had ST-elevation.8 Neither of these registries applied the diagnostic criteria recently proposed by the ESC MINOCA position paper.5

The 1-year mortality rate of 4.5% in our cohort is similar to the mortality rate observed in the International Takotsubo Registry, where rate of mortality rate was 5.6% per patient-year14,15 and two more recent large registries reporting 1-year mortality rates of 4.2%16 and 5.3%17, although these reports did not report specifically on patients with ST-elevation. On the other hand, it contrasts with the absence of major adverse cardiac or cardiovascular events seen over a 2-year follow-up in the HORIZONS-AMI trial in STEMI patients with apical ballooning12 and the 0.05% mortality rate reported in the Swedish Angiography and Angioplasty Register (SCAAR),18 although the latter was not confined to STEMI.

The heterogenous aetiology of MINOCA is further highlighted in our cohort, with coronary causes accounting for only 28% of cases. Approximately 10% of our cohort had a final diagnosis of plaque disruption, which is lower than the 40% incidence in MINOCA patients reported by Reynolds *et al*.19 using intravascular ultrasound or high resolution optical coherence tomography.20 Within our cohort, 2 of 6 patients required the use of intracoronary imaging to establish the diagnosis of spontaneous coronary artery dissection. Only 3% of our cohort had angiographically-apparent coronary spasm, although spasm provocation testing was not undertaken. This is much lower than the incidence in previous reports employing provocative spasm testing where coronary spasm was identified as a cause of MINOCA in ~50% of patients.21 The Coronary Vasomotion Disorders International Study Group (COVADIS)22 has recommended three criteria to diagnose coronary artery vasospastic disorders, that include a clinical history suggestive of vasospasm, documented transient ischaemic ECG changes and presence of coronary artery spasm either spontaneously or in response to provocative stimulation. The gold standard involves the use of provocative stimulus (typically intracoronary acetylcholine) to produce symptoms and signs of spasm. Provocative spasm testing is indicated in MINOCA,22 and has both diagnostic and prognostic importance, as recently shown by Montone *et al*.23,24 The Montone paper showed that provocative spasm testing is safe, even in the acute phases of MINOCA. Non-coronary cardiac-related causes accounted for 61% of cases, the most frequent diagnoses being myocarditis (22%) and Takotsubo syndrome (18%).   
The main limitations of our data are the relatively small, single-centre patient sample size and the retrospective nature of the analysis. Furthermore, coronary spasm provocation testing and intravascular imaging were not routinely performed, and therefore the underlying aetiology may have been inaccurately characterised in some patients. The major strength of our paper is the inclusion of all consecutive, unselected patients, who all met the stringent criteria for STEMI.

# Conclusion

Approximately 4% of patients presenting with STEMI for PPCI have MINOCA. This is the first description of the relatively high incidence of MINOCA in a STEMI cohort using current ESC diagnostic criteria. The heterogenous aetiology highlights the need to actively seek the underlying diagnosis using diagnostic algorithms recommended by the ESC and the COVADIS group.

## Funding

This article is not funded by external sources.

## Disclosures

The authors declare that there are no conflicts of interest to disclose.

# References

1. DeWood MA, Spores J, Notske R, et al. Prevalence of Total Coronary Occlusion during the Early Hours of Transmural Myocardial Infarction. *N Engl J Med* 1980; 303: 897–902.

2. DeWood MA, Stifter WF, Simpson CS, et al. Coronary Arteriographic Findings Soon after Non-Q-Wave Myocardial Infarction. *N Engl J Med* 1986; 315: 417–423.

3. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J* 2017; 39: 119–177.

4. Pasupathy S, Air T, Dreyer RP, et al. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. *Circulation* 2015; 131: 861–870.

5. Agewall S, Beltrame JF, Reynolds HR, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. *Eur Heart J*; 38. Epub ahead of print 28 April 2016. DOI: 10.1093/eurheartj/ehw149.

6. Gehrie ER, Reynolds HR, Chen AY, et al. Characterization and outcomes of women and men with non–ST-segment elevation myocardial infarction and nonobstructive coronary artery disease: Results from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early . *Am Heart J* 2009; 158: 688–694.

7. Larsen AI, Galbraith PD, Ghali WA, et al. Characteristics and outcomes of patients with acute myocardial infarction and angiographically normal coronary arteries. *Am J Cardiol* 2005; 95: 261–3.

8. Lindahl B, Baron T, Erlinge D, et al. Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients With Myocardial Infarction With Nonobstructive Coronary Artery DiseaseClinical Perspective. *Circulation* 2017; 135: 1481–1489.

9. Ghadri J-R, Wittstein IS, Prasad A, et al. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. *Eur Heart J* 2018; 39: 2032–2046.

10. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). *Eur Heart J*. Epub ahead of print 25 August 2018. DOI: 10.1093/eurheartj/ehy462.

11. Ghadri J-R, Wittstein IS, Prasad A, et al. International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management. *Eur Heart J* 2018; 39: 2047–2062.

12. Prasad A, Dangas G, Srinivasan M, et al. Incidence and angiographic characteristics of patients With apical ballooning syndrome (takotsubo/stress cardiomyopathy) in the HORIZONS-AMI trial. *Catheter Cardiovasc Interv* 2014; 83: 343–348.

13. Widimsky P, Stellova B, Groch L, et al. Prevalence of normal coronary angiography in the acute phase of suspected ST-elevation myocardial infarction: experience from the PRAGUE studies. *Can J Cardiol* 2006; 22: 1147–52.

14. Templin C, Ghadri JR, Diekmann J, et al. Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. *N Engl J Med* 2015; 373: 929–938.

15. Ghadri JR, Kato K, Cammann VL, et al. Long-Term Prognosis of Patients With Takotsubo Syndrome. *J Am Coll Cardiol* 2018; 72: 874–882.

16. Hjort M, Lindahl B, Baron T, Jernberg T, Tornvall P, Eggers KM. Prognosis in relation to high-sensitivity cardiac troponin T levels in patients with myocardial infarction and non-obstructive coronary arteries. *Am Heart J* 2018; 200: 60-66.

17. Bainey KR, Welsh RC, Alemayehu W, Westerhout CM, Traboulsi D, Anderson T, Brass N, Armstrong PW, Kaul P. Population-level incidence and outcomes of myocardial infarction with non-obstructive coronary arteries (MINOCA): Insights from the Alberta contemporary acute coronary syndrome patients invasive treatment strategies (COAPT) study. *Int J Cardiol* 2018; 264: 12-17.

18. Tornvall P, Collste O, Ehrenborg E, et al. A Case-Control Study of Risk Markers and Mortality in Takotsubo Stress Cardiomyopathy. *J Am Coll Cardiol* 2016; 67: 1931–1936.

19. Reynolds HR, Srichai MB, Iqbal SN, et al. Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease. *Circulation* 2011; 124: 1414–25.

20. Niccoli G, Scalone G, Crea F. Acute myocardial infarction with no obstructive coronary atherosclerosis: mechanisms and management. *Eur Heart J* 2015; 36: 475–481.

21. Ong P, Athanasiadis A, Hill S, et al. Coronary Artery Spasm as a Frequent Cause of Acute Coronary Syndrome. *J Am Coll Cardiol* 2008; 52: 523–527.

22. Beltrame JF, Crea F, Kaski JC, et al. International standardization of diagnostic criteria for vasospastic angina. *Eur Heart J* 2015; 38: ehv351.

23. Montone RA, Niccoli G, Fracassi F, et al. Patients with acute myocardial infarction and non-obstructive coronary arteries: safety and prognostic relevance of invasive coronary provocative tests. *Eur Heart J* 2017; 39: 91–98.

24. Kaski JC. Provocative tests for coronary artery spasm in MINOCA: necessary and safe? *Eur Heart J* 2018; 39: 99–101.

**Figure Legends**

**Figure 1**

**Flowchart for identification of patients**


For the purposes of this registry, the criteria for definition of myocardial infarction included a positive cardiac biomarker defined as a rise and/or fall in serial levels with at least 1 value above the 99th percentile upper reference limit and clinical evidence of myocardial infarction as evidenced by ischaemic symptoms and/or ischaemic changes manifesting in new ST-segment changes or left bundle branch block. Patients with fixed ST-segment changes without elevation of cardiac enzymes and subsequently labelled as having “normal variant” ECGs, were excluded from analysis.

**Figure 2**


**Prevalence of coronary disease and management of patients presenting with STEMI.**

CAD= coronary artery disease. Numbers in brackets are (%) of total cohort.

**Figure 1**



**Figure 2**

****